NCT03078101View on ClinicalTrials.gov

EMPRA (EMPagliflozin and RAs in Kidney Disease)

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 15, 2017

Primary Completion Date

June 18, 2019

Study Completion Date

August 7, 2019

Conditions
Diabetic Kidney DiseaseDiabetes Mellitus, Type 2Chronic Kidney Disease stage3Chronic Kidney Disease stage4
Interventions
DRUG

Empagliflozin 10 MG [Jardiance]

administered orally once daily

DRUG

Placebo Oral Tablet

administered orally once daily

Trial Locations (1)

1090

Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria, Vienna

Sponsors

Collaborators (1)

Attoquant Diagnostics
All Listed Sponsors
collaborator

Attoquant Diagnostics

UNKNOWN

lead

Medical University of Vienna

OTHER